Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 3:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rho-Kinase Inhibitor Clear all
Recruiting Phase 2 Interventional

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

NCT07006506
View directory record Official record
Conditions
Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy
Interventions
Belumosudil
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 13, 2026, 3:29 AM EDT
Not listed Phase 2 Interventional

Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

NCT03813056
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy
Interventions
Glanatec, Optive, Ophthalmic Solution, Descemet Membrane Endothelial Keratoplasty
Drug · Procedure
Lead sponsor
Michael D. Straiko, MD
Other
Eligibility
30 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 13, 2026, 3:29 AM EDT
Active, not recruiting Phase 2 Interventional

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

NCT05218668
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Fasudil (WP-0512)
Drug
Lead sponsor
Woolsey Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 13, 2026, 3:29 AM EDT
Not listed Phase 2 Interventional

A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

NCT02174991
View directory record Official record
Conditions
Glaucoma
Interventions
Rho-Kinase Inhibitor (AR-12286)
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 13, 2026, 3:29 AM EDT
Terminated Phase 2 Interventional Results available

TGR1202 in Relapsed and Refractory Follicular Lymphoma

NCT03178201
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
TGR-1202
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 13, 2026, 3:29 AM EDT
Not listed Phase 2 Interventional

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma

NCT02152774
View directory record Official record
Conditions
Chronic Angle-closure Glaucoma
Interventions
Rho-Kinase Inhibitor
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
50 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 13, 2026, 3:29 AM EDT
Recruiting Phase 2 Interventional

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT05996627
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil, Biospecimen Collection, Electronic Health Record Review, Placebo Administration
Drug · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Duarte, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 13, 2026, 3:29 AM EDT
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 13, 2026, 3:29 AM EDT
Recruiting Phase 1 Interventional

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

NCT06075810
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
Interventions
MBQ-167
Drug
Lead sponsor
MBQ Pharma
Industry
Eligibility
21 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Beverly Hills, California • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 13, 2026, 3:29 AM EDT
Recruiting Phase 2 Interventional

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

NCT07175038
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
Interventions
ROC-101
Drug
Lead sponsor
AllRock Bio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 13, 2026, 3:29 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

NCT04234932
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 13, 2026, 3:29 AM EDT
Active, not recruiting Phase 3 Interventional

Descemet Endothelial Thickness Comparison Trial I

NCT05289661
View directory record Official record
Conditions
Fuchs
Interventions
Topical Ripasudil, Topical Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Palo Alto, California • Sacramento, California • Palm Beach Gardens, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 13, 2026, 3:29 AM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 13, 2026, 3:29 AM EDT
Not listed Phase 2 Interventional

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

NCT04734379
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Syndrome
Interventions
Fasudil
Drug
Lead sponsor
Woolsey Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 13, 2026, 3:29 AM EDT
Completed Phase 2 Interventional Results available

A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma

NCT01936389
View directory record Official record
Conditions
Exfoliation Syndrome, Ocular Hypertension, Open Angle Glaucoma
Interventions
AR-12286
Drug
Lead sponsor
Robert Ritch, MD, LLC.
Other
Eligibility
50 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 13, 2026, 3:29 AM EDT
Completed Phase 3 Interventional Results available

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

NCT00498615
View directory record Official record
Conditions
Raynaud, Scleroderma
Interventions
Fasudil
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 13, 2026, 3:29 AM EDT
Recruiting Phase 4 Interventional

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

NCT07588152
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution (Rhopressa), Artificial Tears (AT)
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 13, 2026, 3:29 AM EDT
Not listed Phase 2 Interventional

A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt

NCT02173223
View directory record Official record
Conditions
Advanced Glaucoma
Interventions
Rho-Kinase Inhibitor
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 13, 2026, 3:29 AM EDT